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III. Antagonist's Viewpoint
JAY N. COHN, MD, FACC
Minneapolis, Minnesota
Considerable evidence has accumulated during the past
decad : that c.'rfirms the hypothesis that peripheral arterial
and venous constriction may adversely affect the perform-
ance of the failing heart by increasing ventricular preload
and afterload.
(1) . Several laboraaries (2-4) have also
shown that patients with heart failure have activation of
neurohormonal systems (as evidenced by high plasma levels
of nnrepinephrine, renin activity and vasopressin) that may
contribute to systemic vasoconstriction . These observations
have led to the hypothesis that neurohormonal activation is
JACC Vol. 12, No .2
August 19ga,547-58
3x00
V 2000
A
6
1300
0
0
	
500 1008 1500
PNE Pa'-
Figure
1. Poor correlation between plasma norepinephrine (PNE)
concentration and calculated systemic vascular resistance (SVR) in
patictts with congestive heart failure. Reprinted, by permission.
from Lesion et al . (5) .
the primary event that leads to :asoconstriction and that the
neurohormonal activation contributes directly to progres-
sion of' he heart failure syndrome and to sudden death .
I shall attempt in this brief review to provide evidence
against the concept that neurohormonal activation is the sole
contributor to vasoconstriction in this syndrome and that
neurohormonal activation plays a direct pathogenetic role in
progression of the syndrome independent of its vasocon-
strictor effects .
Vasoconstriction is not related to neurohormonal activa-
tion Although it has been attractive to assume that the
sympathetic nervous system and the renin-angiotensin sys-
tem are the major causes of systemic vasoconstriction in
chronic heart failure, the data that are available to support
this concept are not persuasive . There is only a weak
correlation between values for systemic vascular resistance
and plasma norepinephrine and no correlation between
values for systemic vascular resistance and plasma renin
activity or plasma levels of arginine vasopressin (Fig . 1)
(4,5) . If these plasma hormone levels provide a guide to the
degree of activation of these endogenous vasoconstrictor
systems, and if systemic vascular resistance provides a guide
to the intensity of arterial vasoconstriction, then these data
suggest that other factors are important in determining the
increased tone of the arterial vasculature in chronic heart
failure.
Other evidence also supports a role for ,son-neuroendo-
crine factors in the systemic vasoconstriction of chronic
heartfai ure . When patients with heart failure and abnormal
hemodynamics at rest are tilted into the upright position,
systemic vascular resistance increases, but this systemic
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vasoconstriction is not associated with an increase in plasma
norepinephrine or renin activity (6) . Similarly, the rebound
vasoconstriction that follows the abrupt withdrawal of vaso-
dilator drugs (nitroprusside and nitroglycerin, for example)
is not paralleled by changes in circulating neurolsormones
•
and, therefore, does not appear to be due to activation of
neurohormonal mechanisms (7).
Plasma norepinephrine and survival are not linearly re-
•
lated. The relation between high plasma levels of norepi-
nephrine and shortened survival in chronic heart failure, first
demonstrated from our laboratory (8), has been interpreted
by many observers as evidence that activation of the sym-
pathetic nervous system has a direct deleterious effect on the
natural history of this disorder. Some have also suggested
that adrenergic activation contributes directly to the occur-
rence of sudden death in this syndrome . Our original report
(8) on the prognostic value of plasma norepinephrine levels
in heart failure did not support the latter hypothesis, how-
ever, because the high plasma levels of norepinephrine
appeared to correlate more closely with death from pump
failure than with sudden (presumed arrhythmic) death .
Farther analysis of (he relation between plasma norepi-
nephrine and survival in a larger series ofpatients has led to
a revision of our or;ginal conclusions (9). This reanalysis
confirmed our primary observation that patients with a very
high plasma level of norepinephrine had an unfavorable
long-term outcome; however, the relation between plasma
norepinephrine and survival was not linear. The data ap
.
peared to fit most closely a two-compartment model, in that
a plasma norepinephrine concentration >600 pg/ml por-
tended a poor prognosis whereas a concentration <600 pg/mI
portended a more favorable long-term outcome . Within
these two major subgroups, however, no trends in survival
were noted to follow an increase or decrease in plasma
catecholamines . The absence of a linear relation between
plasma norepinephrine and survival in chronic heart failure
suggests that sympathetic activation in itself is not a risk
factor in this syndrome .
Alpha 1-adrenergic blockade is not clinically effective . Fur-
ther evidence against a critical role for the sympathetic
nervous system in the vasoconstriction of heart failure is
obtained from the studies of long-term prazosin therapy in
these patients . Prazosin is an alpha s-adrenoceptor blocking
agent that should effectively inhibit the contribution of
norepinephrine to systemic vasoconstriction. Although
some question has been raised about possible tolerance to
the long-term effects of prazosin . data from several long-
term studies (10) support the view that the drug continues to
exert some sustained vasodilator effect even if this effect
becomes somewhat attenuated with time. Tolerance to pra-
zosin is probably not due to a loss of the drug's alpha,-
adrenergic blocking action but rather appears to
be due to
the activation of other vasoconstrictor systems .
Despite these persistent pharmacologic actions, however,
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prazosin and other alpha,-adrenergic blockers have failed to
produce any favorable effect on exercise tolerance or sur-
vival in several controlled clinical trials
. In the Veterans
Administration Vasodilator Heart Failure Trial (V-HeFr),
survival in patients treated with prazosin was identical to
that in patients treated with placebo, even though blood
pressure was significantly reduced in the prazosin-treated
group (11). In contrast, the nonspecific vasodilator combi-
nation of hydralazine and isosorbide dinitrate significantly
reduced mortality
. If the sympathetic nervous system was
critical to the genesis of vasoconstriction, and if vasocon-
striction was critical to the prognosis of the syndrome, then
we might expect the specific neurohormonal inhibitor prazo-
sin to be more effective than the nonspecific vasodilator
regimen. The opposite result suggests that the sympathetic
nervous system does not play a critical role in the pathoge-
netic link between systemic vasoconstriction, progression of
heart failure and survival .
Relation between circulating and myocardial norepineph-
rine. Some investigators have suggested that the sympa-
thetic nervous system may adversely affect the survival of
patients with congestive heart failure by depleting myocar-
dial norepinephrine and thereby adversely affecting ventric-
ular performance. Studies by Pierpont et al . (12) from our
laboratory, however, have failed to demonstrate a consistent
relation between heightened plasma norepinephrine concen-
tration and reduced myocardial norepinephrine levels . These
data must be viewed with caution because the myocardial
levels of norepinephrine in this study were measured at the
time of heart transplantation, whereas plasma norepineph-
rine was measured days to weeks before the transplantation .
Nonetheless, only a very weak correlation could be demon-
strated between the plasma and myocardial compartments
;
some patients with end-stage heart failure have nearly nor-
mal myocardial levels of norepinephrine . A similar hetero-
geneity is present between myocardial levels of dopamine
and norepinephrine (13) . Most importantly, the severity of
left ventricular dysfunction correlates poorly with changes in
myocardial catecholamines. These data do not support the
hypothesis that sympathetic activation exerts an adverse
effect on the course of heart failure through depletion of
catecholamines in the failing myocardium .
Converting enzyme inhibitors may not work by neurohor-
mnnal inhibition . Angiotensin-converting enzyme inhibition
favorable affects the syndrome of congestive heart failure by
improving exercise tolerance, relieving symptoms, correct-
ing electrolyte deficits and prolonging life (14-16) . Although
it has been assumed that this beneficial effect is related to the
ability of these drugs to lower circulating levels of angiolen-
sin 11, patients without evidence of enhanced neurohormonal
activity (that is, those with low plasma renin activity)
frequently show improvement after treatment with captopril
and enalapril . Several studies have shown that the measure-
ment of plasma renin activity is of no value in identifying
IACC V,,I. 12 . No. 2
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those patients most likely to respond favorably to long-term
converting enzyme inhibition .
To explain the favorable response to converting enzyme
inhibition in low renin heart failure, some observers (17)
have suggested that captopril and enalapril may exert some
of their favorable effects by reducing the activity of the
sympathetic nervous system by virtue of a presynaptic
inhibitory effect on norepinephrine release into the synaptic
cleft
. However, a recent study by Francis et al . (I8) from our
laboratory does not support this hypothesis . Sequential
measurements of plasma norepinephrine were performed in
two groups of patients with heart failure, one treated with a
converting enzyme inhibitor and the other treated with drugs
that did not inhibit the renin-angiotensin system . Over the
course of 54 months of follow-up, plasma norepinephrine
increased progressively in both groups . The increase in
plasma norepinephrine it patients treated with a converting
enzyme inhibitor (11.7 pglml per month), however, was
actually greater than the increase observed in patients not
treated with captopril or enalapril (6 .6 pglml per month)
.
These data do not support the hypothesis that the benefits of
converting enzyme inhibitors are related to their inhibitory
effects on the sympathetic nervous system .
Converting enzyme inhibitors are not superior to direct
vasodilators. If neuroendocrine mechanisms were the pri-
mary culprit in the vasoconstriction of heart failure, then
inhibition of these systems might be expected to have a more
favorable short-term effect on left ventricular function than
would nonspecific vasodilator drugs. Examination of the
available data, however, indicates that the immediate hemo-
dynamic response to alpha,-adrenergic blockade, converting
enzyme inhibition or vasopressin antagonism is less marked
than the hemodynamic response to direct-acting drugs, such
as nitroprusside, hydralazine, minexidil and nitrates (19) .
The observation that the converting enzyme inhibitor
enalapril exerted a favorable effect on survival in the Coop-
erative North Scandinavian Enalapril Survival Study (CON-
SENSUS) trial (20) has been interpretm
: as evidence that
neurohormonal inhibition has a beneficial efi'ect on the
long-term outcome of patients with heart failure . If the
neurohormonal mechanism was critical to thi ; favorable
result, however, then we might anticipate that th
,
reduction
of mortality after converting enzyme inhibition would be
greater than the reduction of mortality seen with a nonspe-
cific vasodilator regimen that does not inhibit reuroendo-
crine mechanisms. Contrary to these expectatiots, the of
fects of enalapril on survival in the CONSENSUS study are
similar to (if not somewhat less than) the effects c n survival
seen with a combination of hydralazine and isosorbide
dinitrate in the V-HeFT study . Although the class IV pa-
tients enrolled in the CONSENSUS trial had a much worse
prognosis than the class 11-III patients evaluated in
V
-HeFT .
i
t is still possible to examine the percent reduction in
mortality produced by the two 'herapeutic regimens. At the
JACC
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Figure 2
. Percent reduction in mortality in chronic heart failure
achieved by treatment with the combination of hydralazine and
isosorbide dinitmte (Hyd-ISDN) in the Veterans Administration
Vasodilator Heart Failure Trial (V-HeFT) (11) and with enalapril in
the Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS) (20) .
end of I year (the longest interval that can be assessed in the
CONSENSUS trial), the mortality rate was reduced by 31%
by enalapril (20) but by 38% with a combination of hydral-
azine and isosorbide dinitrate (I1) (Fig. 2). Such a compari-
son fails to support the concept that neuroendocrine inhibi-
tion is critical to prolonging life in patients with heart failure .
Left ventricular function and exercise tolerance are the
primary determinants of survival in heart failure
. The major
determinants of survival in chronic heart failure are left
ventricular ejection fraction and exercise tolerance, but
neither variable is closely correlated with the plasma con-
centration of norepinephrine (21) . Furthermore, in our expe-
rience, plasma renin activity (measured when the patient is
clinically stable) is not an independent predictor of survival
in chronic heart failure. These data do not support the
suggestion that high circulating levels of vasoconstrictor
neurohormones are themselves a risk factor for mortality .
Further
evidence for left ventricular function as the
primary determinant of survival in chronic heart failure
comes from a recently completed subanalysis of the V-HeFT
data base
(22) . Regardless of the treatment assignment,
patients who demonstrated an increase in the left ventricular
ejection fraction (measured at 3 weeks into the study) had a
better long-term outcome than did patients with little change
or a decrease in ejection fraction. This observation suggests
that neuroendocrine mechanisms are not the major culprit in
progression of the heart failure syndrome .
Conclusions. In summary, three observations support the
hypothesis that neuroendocrne stimulation has a deleterious
effect on the course of congestive heart failure
: I) plasma
norepitsephrine concentration is an independent predictor of
mortality in heart failure; 2) converting enzyme inhibition
has a favorable effect on the long-term outcome of patients
with heart failure; and 3) beta-adrenoceptor blockade may
COHN
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have a favorable effect (in preliminary observations) on the
long-term outcome of some patients with heart failure (23)
.
The evidence that fails to support a primary role for
neurohormonal stimulation in the progression of chronic
heart failure is considerably more persuasive: II vasocon-
striction is not necessarily related to neurohormonal stimu-
lation ; 2) nonspecific vasodilators are as potent or more
potent than neurohormonal inhibitors in improving cardiac
performance in heart failure; 3) alpha,-receptor blockade is
chronically ineffective in heart failure; 4) convening enzyme
inhibition has a favorable long-term effect even in the
absence of heightened neurohormonal activity ; 5) converting
enzyme inhibition does not ,roduce long-term suppression
of plasma norepnephrine coccentration; 6) plasma renin
activity may not be an independent predictor of mortality in
heart failure ; 7) plasma norepinephrine concentration is not
linearly related to mortality or predictive of sudden death ; 8)
nonspecific vasodilators (hydralaziae and isosorbide dini-
trate) and converting enzyme inhibitors produce a similar
prolongation of life in heart failure; 9) ejection fraction and
exercise tolerance are the most powerful predictors of sur-
vival in heart failure and are not closely correlated with
neurohormonal stimulation ; and 10) myocardial norepineph-
rine is not uniformly depleted in patients with heart failure
and such depletion (when present) is not consistently asso-
ciated with an elevation in plasma norepinephrine.
These data appear to support a conclusion that neura-
horrnanal stimulation is a marker for the severity of heart
failure but does nor necessarily play a primary pathogenetic
role in progression ofthe disease
.
Although vasoconstriction
seems to be an important factor in this progression . the
neurohormonal contribution to such systemic vasoconstric-
tion may not be critical
. This conclusion must be tentative,
however, because many unanswered questions remain . Can
neurohormonal inhibition favorably influence the course of
heart failure when it is accomplished without concomitant
vasodilatoon or inhibition of tachycardia? Can neurohormo-
nal inhibition prevent the development of heart failure in
patients with asymptomatic left ventricular dysfunction?
Until these answers are available, we must remain cautious
in assuming that neurohormonal stimulation in itself leads to
progression of congestive heart failure .
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